Bone Metabolism Archive
Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.
Romosozumab increased spine and hip bone mineral density after 12 months of treatment.
Screening with bone measurement is recommended for women. Younger women are at more risk.
High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
Investigators sought to determine whether female reproductive and hormonal factors affect the incidence of total knee arthroplasty for osteoarthritis.
Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.
Vitamin D levels in preterm infants are significantly correlated with optimal calcium homeostasis and bone mineralization of the femur.
Negative effects of 2-hour glucose was pronounced at the cortical-bone-dominant sites in women.
For patients with osteopenia or osteoporosis, taking a bisphosphonate drug holiday is associated with increased risk of fracture for patients with lower femoral neck bone mineral density or T scores.
Investigators sought to determine whether both restrictive and purging types of anorexia nervosa effect bone metabolism.
Studies on the antifracture effectiveness of antiosteoporosis medications (or nonpharmacologic treatments) should account for death as a competing risk.
Anxiety levels are associated with bone mineral density and fracture risk in the lumbar spine and femoral neck among postmenopausal women.
Researchers sought to determine the predictive value of tibiofemoral MRI, patellofemoral MRI, and KLG1 for the incidence of clinical or radiographic knee OA.
A high stress fracture rate in oligo-amenorrheic athletes, who have whole body, less head and hip, areal bone mineral density (BMD) measures comparable to those of control patients, indicates that BMD in these women may need to be even higher to avoid fractures.
The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
Thiazide diuretic use may convey a decreased risk of fracture and as such, the protective effect of this class of medicine should be considered when prescribing thiazide diuretics in clinical practice.
Researchers sought to identify associations of female reproductive factors with incidence of total knee arthroplasty in osteoarthritis.
Anti-osteoporotic medications (mainly bisphosphonates) seem to equally prevent bone loss, especially in the lumbar spine, in patients with diabetes compared with patients without diabetes.
One reason selective serotonin reuptake inhibitors may affect the likelihood of osteoporosis is that the drug antagonizes the serotonin transporter, 5-HTT.
Intermittent use of high-dose glucocorticoids did not increase the risk for any, osteoporotic, hip, or clinically symptomatic vertebral fractures in patients with chronic obstructive pulmonary disease.
Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.
Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.
In this review, 2 independent investigators searched clinical trial databases for studies that evaluated the link between vitamin D supplements and bone health in adult patients with epilepsy.
Abatacept was superior at increasing bone mineral density in the femoral neck compared with other biologic disease-modifying antirheumatic drugs, and may offer good efficacy for improving BMD in rheumatoid arthritis.
Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.
Researchers observed detrimental effects of RYGB on bone turnover, mass, structure, and strength just 6 months postoperatively, and these effects persisted throughout the duration of the 12-month study.
The use of biologic disease-modifying antirheumatic drugs has no medium-term effect on the risk for spinal fractures among patients with ankylosing spondylitis.
Study assessed the effect of denosumab on bone mineral density and incident fractures in older adults with primary hyperparathyroidism who could not undergo or refused surgery.
A lower bone mineral density in the lumbar spine, femoral neck, and hip is associated with an increased risk for intracranial aneurysm.
In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
New findings do not support routine vitamin D and calcium supplementation in community-dwelling older adults for lowering the incidence of osteoporosis-related fractures.
Researchers conducted a long-term follow-up study to determine whether BMD loss, osteoporosis, and fractures were successfully treated or prevented in an urban population of patients with epilepsy and reduced bone density.
Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.
The association between alendronate use and nonvertebral fracture was strongest in patients who received high doses of glucocorticoid.
In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.
Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.
The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.
A single bone mineral density measure and fracture history can predict long-term fracture risk in older women.
According to a study published in the Journal of Bone and Mineral Research, researchers hypothesized that serum K-Postn levels may be able to predict low-trauma fractures.
The effect of 1 year of cross-sex hormone therapy on bone mineral density was examined in transgender men and women.
Daily supplementation with B vitamins and folic acid does not affect fracture risk for women with preexisting CV disease.
Researchers examined the benefits and risks associated with delaying ART initiation to slow bone mineral density loss.
Bone mineral density of the femoral neck, a significant predictor of fracture risk, declined nearly twice as quickly in HIV-infected women compared with HIV-infected men.
The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.
Changes in bone mineral density at 1 year were similar in the immediate and delayed ART groups.
Daytime sleepiness and poor quality of sleep affect recurrent fall risk in the elderly.
Healthy middle-age patients who took colecalciferol did not have a reduced risk for fall or fracture.
Twenty minutes per day of walking or bicycling were associated with a lower rate of fracture.
Participants who lost between 5% and 10% or more than 10% of their body weight slowed knee joint degeneration, compared to those who maintained their current weight.
A 2.5 times higher fracture risk was noted among elderly patients taking sleeping pills.
Long-term denosumab increased bone mineral density in postmenopausal women.
After 1 year of therapy, men who underwent testosterone therapy experienced improvement in bone mineral density and mood.
An update to the 2008 ACP osteoporosis treatment guidelines focuses on treating low bone density and osteoporosis in an effort to prevent fractures.
Tuberculosis was identified as an independent risk factor associated with incident osteoporosis.
Women who had taken oral contraceptives for more than 5 years had the lowest risk for fracture.
Eighty-four percent of survey respondents did not undergo osteoporosis pharmacotherapy following an osteoporosis-related fracture.
Tymlos approval was based on the results of the ACTIVE and ACTIVExtension trials.
Moderate-to-vigorous physical activity was found to be an independent predictor of bone strength in adolescents.
The most common adverse events associated with long-term denosumab use were back, musculoskeletal, or extremity pain, hypercholesterolemia, and cystis.
The most important predictor for use of osteoporosis care was receiving primary care services within 6 months following hip fracture.
Researchers compared the efficacy of dual-energy x-ray absorptiometry with lateral x-ray in assessing vertebral fractures.
Fragility fracture risk increased with older age and decreased with higher bone mineral density in patients with type 1 diabetes.
Using dual-energy X-ray absorptiometry for bone age assessment complements traditional radiologic assessment.
Researchers evaluated trabecular bone scores in more than 100 women during either "legs up" or "legs down" dual energy x-ray absorptiometry scans.
Neither DXA-visceral adipose tissue nor android-gynoid fat mass ratios were associated with atherosclerotic cardiovascular disease events.
The Bone Health TeleECHO Clinic helps telementor healthcare professionals and improves osteoporosis care in underserved communities.
Testosterone treatment improved both bone mineral density and strength in older men.
The effects of repeat doses of antenatal betamethasone were assessed in 185 eligible pediatric patients.
Researchers found that female patients recovering from critical illness respond better to anti-fracture therapy for bone mineral density loss prevention compared with men.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
The long-term effects of several hepatitis virus antivirals on various aspects of bone metabolism are unclear.
Patients taking tenofovir should aim to maximize the phosphorous in their diet.
Ankle fractures presented similar mortality rates between men and women, while other types of fractures had higher mortality rates among men.
Two distinct time trends were observed in initiation of oral bisphosphonates in women after the 2008 updated osteoporosis treatment guidelines.
Patients with psoriatic arthritis or psoriasis had an increased prevalence of osteoporosis risk factors.
Bone Index announced that the Food and Drug Administration (FDA) has granted clearance for the second generation Bindex device model to aid in the diagnosis of osteoporosis.
A prospective cohort study in 66 patients with end-stage renal disease was conducted to determine the link between renal and coronary heart diseases.
Cardiovascular disease, stroke, diabetes, hip and knee replacements, and both behavioral and mental disorders were also more common in the Alzheimer's disease cohort.
Etelcalcetide shows promise for reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.
Less frequent dosing with zoledronic acid does not increase fracture risk in patients with bone metastases.
For patients with type 2 diabetes, long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with fracture risk.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Researchers compared 3 classes of antihypertensive medication to determine hip and pelvic fracture risk in users vs nonusers.
Nancy E. Lane, MD, professor of medicine, at the University of California at Davis School of Medicine, discusses results from the phase 3 ACTIVE trial.
Heavy cannabis users have lower bone density compared to cigarette smokers.
Children and teens who used stimulants for attention-deficit/hyperactivity disorder had lower bone mineral content and bone density than nonusers.
Summer levels of serum 25-hydroxyvitamin D are associated with bone mineral density of the total hip.
The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) announced the publication of new clinical guidelines and an accompanying algorithm to help physicians and other health care professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis.
According to results from the TECOS trial, sitagliptin is not linked to an increased risk for fractures in patients with diabetes.
Study reveals 6-fold higher risk of secondary hyperparathyroidism in patients on furosemide vs hydrochlorothiazide.
Optimism is associated with a decreased fall risk and cynical hostility with an increased fall risk for women.
Higher pericardial adipose volumes were associated with increases in calcified atherosclerotic plaque.
Obese women have significantly greater total vitamin D stores than normal-weight women, although the pattern of distribution of the stores is similar.
In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo.
For postmenopausal women, soy isoflavone supplementation is associated with improvement in bone health.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Trends in Bisphosphonate Use and Hip Fracture Rates in Denmark
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners